Inovio Pharmaceuticals, Inc.
INO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $79,213 | $44,272 | $49,704 |
| - Cash | $36,567 | $24,351 | $39,915 | $65,813 |
| + Debt | $7,282 | $10,658 | $11,271 | $11,865 |
| Enterprise Value | – | $65,520 | $15,628 | -$4,244 |
| Revenue | $0 | $0 | $65 | $117 |
| % Growth | – | -100% | -44.1% | – |
| Gross Profit | $0 | -$742 | $65 | -$659 |
| % Margin | – | – | 100% | -563.1% |
| EBITDA | -$44,747 | -$22,778 | -$18,951 | -$18,606 |
| % Margin | – | – | -29,002.7% | -15,903.3% |
| Net Income | -$45,497 | -$23,519 | -$19,695 | -$19,382 |
| % Margin | – | – | -30,140.5% | -16,566.4% |
| EPS Diluted | -0.87 | -0.61 | -725.11 | -0.7 |
| % Growth | -42.6% | 99.9% | -103,487.1% | – |
| Operating Cash Flow | -$21,573 | -$20,811,359 | -$26,874 | -$19,664 |
| Capital Expenditures | -$68 | $0 | -$59 | $0 |
| Free Cash Flow | -$21,641 | -$20,811,359 | -$26,933 | -$19,664 |